Additional Information & Links

The gold standard test for detection of neutralizing antibodies uses live virus and cells, making it dangerous, expensive, slow, and not practical for routine diagnostic use. The cPASS™ test is a “surrogate” laboratory test, meaning that it does not require live virus; cPASS™ is just as accurate as the live virus tests at detecting neutralizing antibodies, but it is rapid and inexpensive.

Granger Genetics collaborated closely with the test manufacturer (GenScript, Piscataway, NJ) during the clinical validation of the cPASS™. The cPASS™ diagnostic test has already received its CE-IVD approval in Europe and HSA approval in Singapore. FDA approval is expected within weeks (EUA application #200661). Learn more about the cPASS™ Neutralizing Antibody test by clicking on the links below.

https://apnews.com/b4c1ca7c9f1841a09d59efaca5b85c95

https://www.prnewswire.com/news-releases/genscript-files-for-emergency-use-authorization-of-rapid-sars-cov-2-neutralization-antibody-detection-kit-301069883.html

https://www.bioworld.com/articles/435546-genscript-seeks-eua-for-test-that-indicates-immunity-to-covid-19

https://www.genscript.com/cpass-sars-cov-2-neutralization-antibody-detection-Kit.html

Scroll to top